September 2017 Surety Medicine Teleconference:
Abuse, Dependence and Substance Use
Disorders: DSM-IV-TR vs. DSM-5
WEDNESDAY, 27 September 2017 will bring the next Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time. The topic for September is "Abuse, Dependence and Substance Use Disorders: DSM-IV-TR vs. DSM-5.” This discussion of Army surety medical support considerations related to different versions of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders will be led by the Army Public Health Center's senior occupational health physician.
To receive access information for attending the presentation by dial-in phone audio or on your computer via Defense Collaboration Services (DCS), send an email request to:
usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil
______________________________________________________________
New!
SCHEDULE OF SURETY MEDICINE TELECONFERENCES FOR FY 2018
|
18 OCT 2017 |
Updates on Patient Decontamination and the Use of RSDL |
|
15 NOV 2017 |
Emergency Essential Civilian Employees and the PRP |
|
13 DEC 2017 |
Diagnosis/Evaluation/Treatment of Laboratory Acquired Alpha Virus Infections |
|
17 JAN 2018 |
Screening for Dementia and Cognitive Impairments: PRP Suitability & Reliability |
|
21 FEB 2018 |
Ergonomics and the Personnel Reliability Program |
|
21 MAR 2018 |
Updates in the Diagnosis and Treatment of Nerve & Vesicant Agent Exposures |
|
18 APR 2018 |
Hearing Conservation and Audiometric Testing in Surety Programs |
|
16 MAY 2018 |
HIV: CD4 Counts, Antiretroviral Drugs, and Impaired Immune Functions in PRP |
|
27 JUN 2018 |
Medical Review Officer Functions, and Relevant PRP Interfaces |
|
18 JUL 2018 |
Screening Diabetics for Reliability and Suitability in the PRP |
|
15 AUG 2018 |
Case Studies in Personnel Reliability Program Surety Management |
|
26 SEP 2018 |
Animal Worker Occupational Health Issues in the PRP |
______________________________________________________________________________
ALERT: FDA Simplifies Rule for Anthrax PEP
FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS
The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax. The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.
Additional information is available from the FDA at:
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm
ALERT: Autoinjector Shelf Life Extension Program: UPDATED JULY 5, 2017
NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM: Many expiration date extensions for autoinjector medications expire in 2017!
Check any auto-injector medication stores you have. Select the link
below for additional information from the FDA.
The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labeled expiration dates, some are now extended to 2022. Complete FDA information related to the auto-injector shelf life extension program can be found at: http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .
Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors.
_______________________________________________________________